PedAM
Pediatric Disease Annotations & Medicines
| Disease | lung disease |
| Phenotype | C0036421|systemic sclerosis |
| Sentences | 39 |
| PubMedID- 25665185 | Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. |
| PubMedID- 23588945 | Can serum surfactant protein d or cc-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis. |
| PubMedID- 23341987 | Fibrocytes have been implicated in the pathophysiology of other fibrotic lung disorders, such as interstitial lung disease associated with systemic sclerosis (ssc-ild), where fibrocytes have been shown to be increased in the peripheral blood and to accumulate in the lung [9]. |
| PubMedID- 26392856 | We discuss a case that demonstrates the difficulties in making a confident diagnosis of interstitial lung disease (ild) associated with systemic sclerosis (ssc). |
| PubMedID- 24814462 | Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis. |
| PubMedID- 21996293 | Increased frequency of circulating th22 in addition to th17 and th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. |
| PubMedID- 25629053 | Objective: to evaluate the performance of a computerized-aided method (cam) for quantification of interstitial lung disease (ild) in patients with systemic sclerosis and to determine its correlation with the conventional visual reader-based score (covr) and the pulmonary function tests (pfts). |
| PubMedID- 26370615 | Pulmonary fibrosis is a common characteristic of ipf and systemic sclerosis with interstitial lung disease (ssc-ild)7; however, the most common histological pattern observed in ipf is usual interstitial pneumonia (uip), while the pattern most commonly observed in ssc-ild is nonspecific interstitial pneumonia (nsip)8. there is some controversy regarding the pathophysiology of uip and nsip. |
| PubMedID- 22015621 | Intravenous cyclophosphamide pulse therapy (ivcy) exerts its efficacy against interstitial lung disease (ild) associated with systemic sclerosis (ssc) by restoring vascular injuries as well as aberrant immune activation. |
| PubMedID- 23940607 | The muc5b variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the european caucasian population. |
| PubMedID- 21978705 | systemic sclerosis (ssc) is associated with interstitial lung diseases. |
| PubMedID- 23378460 | Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. |
| PubMedID- 26142172 | The main characteristic is a systemic sclerosis-like picture of slowly progressing interstitial lung disease consistent with lung fibrosis, while pulmonary arterial hypertension is rare. |
| PubMedID- 20404807 | Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. |
| PubMedID- 25650330 | Introduction: interstitial lung disease occurs frequently in patients with systemic sclerosis (ssc). |
| PubMedID- 21458128 | Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. |
| PubMedID- 23533311 | Elevated levels of il-10 and enhanced production of il-10 by alveolar macrophages have been reported in several fibrotic diseases, including ipf [221–223] and in systemic sclerosis patients with interstitial lung disease [213]. |
| PubMedID- 26079155 | Exhaled nitric oxide (no) is increased as a result of lung inflammation, which in turn causes subsequent interstitial lung disease in patients with systemic sclerosis (ssc). |
| PubMedID- 25709096 | Where are we going in the management of interstitial lung disease in patients with systemic sclerosis. |
| PubMedID- PMC3329084 | These findings suggest that the development of pulmonary arterial hypertension is probably independent of the existence of interstitial lung disease in patients with systemic sclerosis. |
| PubMedID- 25282395 | Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (ssc-ild): efficacy of maintenance immunosuppression in responders and non-responders. |
| PubMedID- 23764864 | Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease. |
| PubMedID- 23660398 | Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. |
| PubMedID- 22610787 | Objective: to investigate the clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide (ivcy) in systemic sclerosis (ssc) patients with interstitial lung disease (ild). |
| PubMedID- 26315813 | Objectives: to evaluate a new ultrasound sign, pleural irregularity (pi), for the study of interstitial lung disease (ild) in patients with systemic sclerosis (ssc) and antisynthetase syndrome (ass). |
| PubMedID- 23697634 | Background: to determine the usefulness of ca 15.3 as a candidate biomarker in systemic sclerosis (ssc) patients with interstitial lung disease (ild). |
| PubMedID- 24801572 | The aim of this study was to evaluate efficacy of azathioprine (aza) and cyclophosphamide (cyc) as a therapeutic regimen for interstitial lung disease associated with systemic sclerosis (ssc). |
| PubMedID- 24838199 | Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct. |
| PubMedID- 25300701 | Objectives: to assess the long-term efficacy and safety of single and multiple courses of rituximab therapy in systemic sclerosis (ssc) patients with and without lung disease. |
| PubMedID- 21618205 | Objective: patients with systemic sclerosis-associated interstitial lung disease (ssc-ild) are thought to have the greatest decline in lung function (forced vital capacity [fvc]% predicted) in the early years after disease onset. |
| PubMedID- 22972016 | Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. |
| PubMedID- 21538327 | systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. |
| PubMedID- 22075605 | We aimed to investigate the clinical significance of serum levels of secretory leukocyte protease inhibitor (slpi), which is widely expressed in lung tissues and serves as a useful marker reflecting the activity of various lung diseases, in patients with systemic sclerosis (ssc). |
| PubMedID- 22540429 | Serum levels of adam12-s: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis. |
| PubMedID- 23925736 | Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. |
| PubMedID- 21474572 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. |
| PubMedID- 25624597 | Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. |
| PubMedID- 22084615 | Reduced hypoxia risk in a systemic sclerosis patient with interstitial lung disease after long-term pulmonary rehabilitation. |
| PubMedID- 23401350 | Does c-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis. |
Page: 1